1- Indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis.
2- Maintenance of healing of erosive esophagitis.
3- Symptomatic gastroesophageal reflux disease.
4- Risk reduction of NSAID- associated gastric ulcer.
5- H. pylori eradication to reduce the risk of duodenal ulcer recurrence.
6- Triple therapy (Naxiprazol plus amoxicillin and clarithromycin).
|
|||
|
|
